Clinical Trial
MagSense® HER2 Imaging Agent (MSH2IA) Phase I Clinical Study – IBI010103
Imagion Biosystems has recently concluded an investigational Phase I study of a novel molecular imaging agent. This first-in-human study investigated the safety of the MagSense® HER2 Imaging Agent (MSH2IA) and the feasibility of MRI detection of metastatic disease in the axillary nodes in patients with HER2-positive (HER2+) primary breast cancer.
MSH2IA is specifically designed for breast cancer patients who test positive for the Human Epidermal Growth Factor Receptor 2 (HER2). This study has shown that this molecular MRI contrast agent is safe and has the potential to non-invasively determine if breast cancer has spread to the lymph nodes.
Details of the study can be found at Australia New Zealand Clinical Trial Registry
See our most recent data from the SABCS 2023 scientific poster.
If you are interested in learning more, please contact Imagion Biosystems
MagSense® Technology will transform cancer diagnosis
- Non-invasive – a safe and non-surgical solution to detect cancer
- No radioactivity – uses bio-safe magnetic nanoparticles to “tag” cancer cells
- Specific – use of targeted imaging agent provides molecular confirmation of the presence of cancer not just a suspicion
- Platform technology – can be used for many cancers as well as other diseases